Switzerland

Switzerland's primary regulatory authority for therapeutic products is Swissmedic, operating under the Federal Act on Therapeutic Products (Heilmittelgesetz, HMG/LPTh), which governs the authorization, surveillance, and market control of medicinal products, medical devices, and diagnostics. Swissmedic operates independently of the European Medicines Agency (EMA) but maintains a close and cooperative relationship with EU regulatory bodies, applying rigorous standards that are broadly harmonized with EU frameworks. All health products intended for the Swiss market must obtain a Swissmedic marketing authorization or conformity assessment prior to commercialization, with review processes varying by product category and risk classification. Medical devices are regulated under the Swiss Medical Devices Ordinance (MepV/ODim), which was substantially revised in 2022 to align with the EU Medical Device Regulation (EU MDR 2017/745) and EU In Vitro Diagnostic Regulation (EU IVDR 2017/746). Digital health applications may be classified as medical devices and are subject to corresponding conformity requirements depending on their intended purpose and risk profile.

For pharmaceutical products, submissions to Swissmedic follow the Common Technical Document (CTD) format, consistent with ICH guidelines, and Switzerland participates in the ICH framework as a founding member. Applicants based outside Switzerland are required to appoint a locally domiciled Swiss authorization holder or representative. Swissmedic offers several application pathways including standard review, fast-track procedures for products of major therapeutic interest, and recognition procedures that leverage prior approvals by reference authorities such as the EMA or the US FDA. The 2019 revision of the HMG introduced simplified authorization procedures for certain generics and hybrid applications. For medical devices, CE marking under EU MDR or EU IVDR is generally recognized in Switzerland following the update of the Mutual Recognition Agreement (MRA) with the EU, though the MRA annex on medical devices has faced prolonged suspension due to bilateral political tensions, requiring manufacturers to pursue separate Swiss conformity pathways in the interim. Ongoing regulatory reforms continue to monitor and adapt to evolving EU standards and international harmonization initiatives.

Switzerland operates a highly decentralized procurement landscape shaped by its federal structure, which distributes significant authority across 26 cantons. Public healthcare is primarily financed and administered at the cantonal level, with hospitals and outpatient providers largely responsible for their own procurement decisions within the framework of cantonal regulations. The Federal Office of Public Health (FOPH, Bundesamt fur Gesundheit, BAG) plays a central role at the national level, particularly in determining reimbursement conditions for pharmaceuticals through the Specialties List (Spezialitdtenliste, SL) and for medical devices and diagnostics through the Means and Appliances List (Mittel- und Gegenstandeliste, MiGeL). Pricing and reimbursement negotiations for listed products are conducted with the FOPH and are subject to periodic reassessment, with external reference pricing applied to pharmaceuticals using comparator markets including Germany, France, Austria, the United Kingdom, the Netherlands, Belgium, and Denmark. Cantonal hospital procurement is often coordinated through group purchasing organizations (GPOs) such as H+ Die Spitaler der Schweiz affiliated networks, enabling aggregated tendering to achieve cost efficiencies. The Federal Act on Public Procurement (BoeB/LMP), revised and effective from 2021, governs federal-level tenders and aligns Swiss procurement rules more closely with WTO Government Procurement Agreement (GPA) standards, promoting transparency and competitive bidding.

The private sector constitutes a substantial portion of the Swiss healthcare market, with private hospitals, outpatient clinics, and pharmacy chains operating independently and making procurement decisions based on their own commercial criteria, negotiations with distributors, and reimbursement list status. Switzerland is a high-income country and does not typically receive procurement support from multilateral donors such as UNICEF Supply Division, the Global Fund, Gavi, or USAID, which are more commonly active in low- and middle-income country markets. However, Swiss entities including the Swiss Agency for Development and Cooperation (SDC) and private foundations headquartered in Switzerland are significant contributors to global health procurement financing in other markets. Local manufacturing preference policies are not a prominent feature of Swiss procurement regulation; market access is governed primarily by product quality, regulatory compliance, and pricing criteria. Nonetheless, Switzerland hosts a globally significant pharmaceutical and medtech manufacturing base, and there is ongoing policy interest in supply chain resilience and domestic production capacity, particularly following lessons drawn from the COVID-19 pandemic.